News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Silence Therapeutics plc Says Drug Completes Pre-clinical Study
September 10, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 10 (Reuters) - British biotechnology company Silence Therapeutics Plc (SLN.L: Quote, Profile , Research) said on Monday that its lead compound Atu027 had successfully completed pre-clinical, 28-day toxicology studies.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Obesity
Novo Bounces Back With ‘Competitive’ Mid-Stage Weight Loss Data for Amycretin
November 25, 2025
·
2 min read
·
Tristan Manalac
Cancer
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma
November 25, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
November 24, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
November 24, 2025
·
3 min read
·
Heather McKenzie
